Real world risk of discontinuing oral anticoagulation after successful catheter ablation for atrial fibrillation.

ABSTRACT:

Background

Many patients with atrial fibrillation (AF) discontinued oral anticoagulation (OAC) therapy after successful catheter ablation. We aimed to determine the real-world risks and consequences of discontinuing OAC use after catheter ablation for AF.

Methods

Patients who underwent successful catheter ablation for AF from January 2004 to December 2020 were divided into continued long-term OAC (On-OAC, n = 1062) and discontinued (Off-OAC, n = 1055) groups. The long-term outcomes including thromboembolic events, major bleeding, all-cause mortality and major adverse cardiovascular events (MACE), were compared between the two groups.

Results

The CHA2DS2-VASc score was 3.44 ± 1.12. After a mean follow-up of 37.09 months, thromboembolism risk was higher and major bleedi

SUBMITTER: Fei ZT 

PROVIDER: S-EPMC11237919 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature